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A tale of two siblings: two cases of AML arising from a single
pre-leukemic DNMT3A mutant clone
Leukemia (2015) 29, 2101–2104; doi:10.1038/leu.2015.67
Acute myeloid leukemia (AML) patients with DNA methyl-
transferase 3A (DNMT3A) mutations in remission after induction
chemotherapy may have hematopoiesis arising from a putative pre-
leukemic clone lacking the full spectrum of mutations seen at AML
diagnosis.1,2 DNMT3A mutations in hematopoietic stem cells lead to
increased self-renewal capacity and dominance of the stem-cell
compartment.2 The common DNMT3AR882H mutation is usually
heterozygous and results in loss-of-function with a dominant-
negative effect. DNMT3A mutations are thought to occur early in
AML ontogeny,3 and are found in around 20% of de novo AML and
in a higher proportion of secondary AML cases.4,5 In population
studies clonal mutations of DNMT3A6 and other epigenetic
regulators are more common with increasing age, and may
contribute to a proportion of cases of age-related skewing of
X-chromosome inactivation.1,7 Two recent reports from large cohorts
identiﬁed DNMT3A, Tet methylcytosine dioxygenase 2 (TET2) and
additional sex combs like transcriptional regulator 1 (ASXL1;
epigenetic modifying genes) as the most commonly mutated genes
in peripheral blood samples,8,9 with a combined prevalence of
⩾10% in individuals aged over 65 years. One study provided
evidence that individuals with clonal hematopoiesis are more likely
to develop hematopoietic malignancy, and examined in detail
subsequent myeloid malignancy diagnosis samples together with
the initial asymptomatic blood samples for three cases.8 All three
cases were found to have multiple (2–6) known pathogenic
mutations at the time of asymptomatic blood sampling suggesting
that clonal hematopoiesis could be attributed to outgrowth of early
leukemic cells. Importantly, a number of the driver mutations were
only found upon detailed genetic analysis of the initial blood
sample. A similar observation was recently reported in chronic
myeloid leukemia, where a DNMT3A mutation that was discovered
in molecular remission after treatment was also present in the
leukemic clone at diagnosis.10 Hence, although these studies imply
that, at least in some cases, a pre-leukemic clone carrying a single
epigenetic founder mutation may be present for some time prior to
the development of neoplasia, they do not provide direct evidence
of its pathogenicity.
Here we report direct evidence to ﬁll this knowledge gap that a
pre-leukemic clone can evolve to AML. Clonal hematopoiesis
(DNMT3AR882H) was transplanted from an apparently healthy
marrow donor to his brother, with subsequent evolution to
genetically distinct AML clones in each brother. A healthy 53-year-
old man with normal blood counts and bone marrow morphology
donated steady-state bone marrow to his 49-year-old brother for
treatment of relapsed lymphoma. Fourteen months after the bone
marrow transplant, the donor developed normal karyotype AML
with mutations in DNMT3A, nucleophosmin 1 (NPM1), and fms-like
tyrosine kinase 3 (FLT3). Four months later (18 months post-
allograft) the recipient developed normal karyotype AML with
identical mutations in DNMT3A and NPM1, but wild-type FLT3.
Chimerism analysis conﬁrmed donor-derived leukemia. Both
brothers received induction chemotherapy and both relapsed
after a short-lived remission.
Whole-exome sequencing and targeted massively parallel
sequencing of 29 genes recurrently mutated in myeloid malig-
nancies (Supplementary Information) identiﬁed a somatic
DNMT3AR882H mutation that dominated donor hematopoiesis (allelic
burden 46%), despite normal blood counts and morphology. This
clone was transplanted to the recipient, who later developed AML
with a mutational proﬁle distinct from that seen in the donor
(Figure 1 and Supplementary Table 1). The DNMT3A mutation
persisted at transformation to AML and at relapse. Of the multiple
somatic mutations, other than DNMT3A, only NPM1 (W288Cfs*12)
was identical in both brothers. This mutation was not detected in an
aliquot of the transplanted bone marrow harvest product (sensitivity
o0.1%). W288Cfs*12 is the most common NPM1 mutation in AML,
accounting for almost 80% of variants.11 Most DNMT3A-mutant AML
cases also have an NPM1 mutation,12 and the latency period was
longer than that predicted from the known kinetics of NPM1 AML,13
so the presence of this mutation in both brothers likely reﬂects the
propensity for these mutations to co-occur in AML.
In addition known pathogenic mutations were identiﬁed in FLT3
and Isocitrate dehydrogenase 1 (IDH1) in the donor AML, as well
as a novel NOTCH4 mutation. Mutations in NOTCH1 and NOTCH2
are found in hematological malignancies,14 but NOTCH4mutations
have not previously been reported in AML. In the recipient we
identiﬁed an additional mutation in the Structural Maintenance of
Chromosomes 1A (SMC1A) gene, which is a member of the
cohesin complex: recurrent mutations in the cohesin complex
were recently identiﬁed in ~ 12% of AML cases, and are associated
with NPM1 mutations.15
DNMT3A-mutant hematopoiesis persisted in both brothers at
remission after chemotherapy (Figures 1a and b), consistent with
the reported chemoresistance of DNMT3A-mutant clones. The
high DNMT3AR882H allelic burden (likely490% of cells carried the
mutation), and the disappearance of additional pathogenic
mutations indicated reversion to the pre-leukemic clone in
remission. In addition, both brothers had minimal residual disease
(MRD). In the donor this was evident retrospectively at AML
relapse with all earlier mutations plus an additional known
pathogenic Wilms’ Tumor 1 (WT1R394W) mutation (Figure 1a)
which is associated with poor outcome. The recipient was not
tested at relapse (sample not available), but in remission the NPM1
mutation was detected using very deep sequencing at ~ 0.01%
(Figure 1b), consistent with MRD. There was no evidence from the
sequencing data of a familial genetic predisposition to cancer: no
known pathogenic germline mutations were identiﬁed.
We also studied the persistence of DNMT3A mutations in
remission in de novo AML by sequencing remission samples from
12 additional patients with a DNMT3A mutation at diagnosis. We
identiﬁed persistence of the mutation in morphological remission
in 8/12 patients (75%; Supplementary Table 2 and Figure 2)
whereas all concurrent pathogenic AML-associated mutations
were undetectable in available remission samples (Supplementary
Table 2), consistent with previous reports.1,2,16 Interestingly, of the
four patients with a persistent DNMT3A mutation in multiple
remission samples, the mutant allelic burden expanded over time,
whereas peripheral blood counts and morphology remained
normal. If polyclonal hematopoiesis is not restored in remission,
the re-emergence of AML may be due either to failure to eradicate
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MRD or to the independent evolution of a second AML derived
from the original pre-leukemic clone. Available data suggest that
MRD is the dominant cause of relapse.
A striking feature of this case was the relatively short latency
period to the emergence of AML in both brothers (Figure 1c).
Whereas it is often assumed that immunosuppression of the
transplant recipient may contribute to the risk of donor-derived
leukemia,17 the latency periods in the healthy donor and
in the immunosuppressed transplant recipient were similar.
We speculate that the high allelic burden of the DNMT3A
mutations might have been a contributing factor in these two


























































































































































































































Germline Single somatic 
mutation










































Figure 1. Mutational evolution of independent AMLs in two brothers. Mutation proﬁles of the donor (a) and recipient (b) brothers prior to
AML diagnosis, at diagnosis, in remission, and at relapse. (c). Schematic of mutation acquisition and clonal expansion in donor and recipient
bone marrow during independent evolution of their AMLs. All previously acquired mutations persisted in diagnosis samples and donor
relapse sample. In the donor, all mutations present in the diagnosis sample persisted at relapse. A relapse sample from the recipient was not
available. NPM1 detected at * ~ 0.01%. MSC, mesenchymal stromal cells; Dx, diagnosis; CR1, complete remission; Rel, relapse; BMT, bone
marrow transplantation; CTx, conditioning chemotherapy.
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that higher allelic burdens were associated with an increased risk
of subsequent neoplasia.9 This study provides for the ﬁrst time
direct evidence that a single pre-leukemic mutation can promote
evolution to hematopoietic malignancy; in this case, not only one
but two genetically distinct AML clones.
A number of clinically important questions arise from this case.
For AML cases with DNMT3A (or functionally similar) mutations,
should mutational analysis in remission be used to guide the post-
remission therapy? In our series of 12 cases of de novo AML, the
rate of relapse was high irrespective of the persistence of the
DNMT3A mutation in remission. Ploen et al.16 reported relapse in
only 50% of DNMT3A-mutant AML patients with the mutation
present in remission, but allogeneic stem-cell transplantation
would be offered to most individuals in this setting. Transplanta-
tion may potentially eradicate both AML and its antecedent clone.
What is the implication of pre-leukemic mutations for the
monitoring of MRD? A founder mutation that is present in a
pre-leukemic clone may not be a reliable indicator of AML
remission status. Genomic proﬁling of AML could be used to select
the best target(s) for MRD analysis: one or more genes that are
part of the evolved clone. Lastly, is there a case for mutation
screening for a deﬁned panel of potential pre-leukemic mutations
as part of the allogeneic stem-cell donor assessment? On the basis
of recent reports,6,7,9 it would appear that the population
prevalence of such mutations might be sufﬁcient for screening
to be justiﬁed in selected populations (e.g., older donors, or those
with a personal or familial history of malignancy). What is needed
to inform this decision is a better understanding of the natural
history of such clones, and the associated risk of emerging
hematopoietic malignancy.
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Figure 2. Persistence of DNMT3A mutations in complete remission. The allelic burden of DNMT3A (R882H/C) mutation was measured using a
custom Sequenom assay in serial samples from a cohort of 12 additional patients with DNMT3A-mutant AML, those in whom the mutation
was detected during complete remission are shown. Active AML (black), remission (red). Sample types—Dx (diagnosis), CR1 (ﬁrst complete
remission), CR2 (second complete remission), Rel (relapse), P1 (ﬁrst sample post-BMT), P2 (second sample post-BMT). Numbers along x-axis are
time after diagnosis (months).
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Effect of genetic proﬁling on prediction of therapeutic
resistance and survival in adult acute myeloid leukemia
Leukemia (2015) 29, 2104–2107; doi:10.1038/leu.2015.76
Therapeutic resistance, that is failure to achieve complete
remission (CR) despite not incurring treatment-related mortality
(TRM), or relapse after achieving CR, is the principal cause of failure
in acute myeloid leukemia (AML). Many clinical, cytogenetic, and
molecular characteristics are strongly associated with resistance.1
However, using areas under receiver operating curves (AUCs) to
quantify their predictive ability in 44500 younger and older
adults with newly diagnosed AML, we recently demonstrated that
such data, even when combined, provided only limited ability
(AUCo0.8) to predict resistance.2 Greater ability (AUC40.90–
0.95) to forecast resistance to standard therapy in individual
patients might obviate the need to randomize between standard
and investigational treatments, optimize care algorithms and
ultimately beneﬁt patients.
Our previous analysis included molecular data pertaining only
to NPM1 mutations and FLT3/ITDs. At that time, we hypothesized
that consideration of mutational data for other genes might
improve predictive accuracy. Indeed, by proﬁling close to 20
genes, Patel et al.3 were able to separate participants of a recent
Eastern Cooperative Oncology Group (ECOG) phase 3 trial (E1900)
with cytogenetically deﬁned intermediate-risk AML into three
subgroups with signiﬁcantly different outcomes. Here, we
investigated the extent to which prediction of resistance and
survival can be improved by inclusion of detailed molecular data
in the E1900 study cohort. Our study also offered the opportunity
to assess whether CD25, a marker that has shown to improve risk
classiﬁcation independent of other established biomarkers in the
E1900 cohort, could further improve the accuracy of outcome
prediction in individual patients.4
E1900 (NCT00049517) was a randomized trial that compared
daunorubicin doses of 45 and 90mg/m2 each given on days 1–3
together with standard-dose cytarabine in 657 patients aged 17–
60 years with newly diagnosed AML.5 Of these, 398 patients had
sufﬁcient material available for complete genetic proﬁling (see
below).3 Institutional review boards of participating institutions
approved all protocols, and patients were treated according to the
Declaration of Helsinki.
For our analysis, early death TRM was deﬁned as death within
28 days after initiating therapy6 or study registration, if the date of
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